Up-regulation of ECT2 is Associated with Poor Prognosis in Gastric Cancer Patients

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Feb 13

PMID 25674238

Citations 18

Authors

Yi Jin

Yuhui Yu

Qinshu Shao

Yingyu Ma

Ruxuan Zhang

Haibo Yao

Yuan Xu

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to investigate the expression of ECT2 in gastric cancer and its clinical significance.

Methods And Results: We investigated the differentially expressed genes between gastric cancer tissues and normal gastric mucosa by cDNA microarray, and then we found ECT2 was up-regulated in gastric cancer. What is more, we verified ECT2 expression level by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and measured its protein level by immunohistochemistry (IHC). qRT-PCR analysis indicated ECT2 was significantly up-regulated in gastric cancer and Immunohistochemistry confirmed the percentage of ECT2-positive specimens was significantly higher in gastric carcinoma than in non-tumor tissues. Up-regulation of ECT2 is associated with the degree of histological differentiation (P = 0.007), invasion depth (P = 0.047), lymph node metastasis (P = 0.016), distant metastasis (P = 0.021) and TNM stage (P = 0.016), patients with up-regulated ECT2 had a lower overall survival rate (P = 0.000). Cox regression analysis revealed that up-regulation of ECT2 is an independent prognostic factor in gastric cancer patients (P = 0.012).

Conclusion: Up-regulation of ECT2 might contribute to the progression of gastric carcinogenesis and may be a useful prognostic indicator in gastric cancer.

Citing Articles

RHOA drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.

Schaefer A, Hodge R, Zhang H, Hobbs G, Dilly J, Huynh M Sci Signal. 2023; 16(816):eadg5289.

PMID: 38113333 PMC: 10791543. DOI: 10.1126/scisignal.adg5289.

A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target.

Zaki M, Eldeen M, K Abdulsahib W, Shati A, Alqahtani Y, Al-Qahtani S Diagnostics (Basel). 2023; 13(9).

PMID: 37175004 PMC: 10178510. DOI: 10.3390/diagnostics13091613.

Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy.

Soltan M, Eldeen M, Sajer B, Abdelhameed R, Al-Salmi F, Fayad E Biology (Basel). 2023; 12(4).

PMID: 37106813 PMC: 10135641. DOI: 10.3390/biology12040613.

Identification of key genes and carcinogenic pathways in hepatitis B virus-associated hepatocellular carcinoma through bioinformatics analysis.

Kim S, Hwang S, Song G, Jung D, Moon D, Yang J Ann Hepatobiliary Pancreat Surg. 2021; 26(1):58-68.

PMID: 34907098 PMC: 8901975. DOI: 10.14701/ahbps.21-108.

Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.

Cook D, Kang M, Martin T, Galanko J, Loeza G, Trembath D Cancer Res. 2021; 82(1):90-104.

PMID: 34737214 PMC: 9056178. DOI: 10.1158/0008-5472.CAN-20-4218.

References

Gravalos C, Jimeno A . HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008; 19(9):1523-9. DOI: 10.1093/annonc/mdn169. View

Yang L . Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006; 12(1):17-20. PMC: 4077485. DOI: 10.3748/wjg.v12.i1.17. View

Tamura G . Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006; 12(2):192-8. PMC: 4066026. DOI: 10.3748/wjg.v12.i2.192. View

Gomez del Pulgar T, Benitah S, Valeron P, Espina C, Lacal J . Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005; 27(6):602-13. DOI: 10.1002/bies.20238. View

Solski P, Wilder R, Rossman K, Sondek J, Cox A, Campbell S . Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation. J Biol Chem. 2004; 279(24):25226-33. DOI: 10.1074/jbc.M313792200. View

Rossman K, Der C, Sondek J . GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005; 6(2):167-80. DOI: 10.1038/nrm1587. View

Wang Y, Ye Z, Zhao Z, Tao H, Li S . Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer. J Cancer Res Clin Oncol. 2009; 136(1):135-41. DOI: 10.1007/s00432-009-0644-y. View

Huff L, DeCristo M, Trembath D, Kuan P, Yim M, Liu J . The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes Cancer. 2014; 4(11-12):460-75. PMC: 3877668. DOI: 10.1177/1947601913514851. View

Huang C, Zhao J, Lv L, Chen Y, Li Y, Jiang S . Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer. PLoS One. 2013; 8(7):e69155. PMC: 3720544. DOI: 10.1371/journal.pone.0069155. View

10.

Zhang Q, Jin X, Yang Z, Wei M, Liu B, Gu Q . Upregulated Hoxc6 expression is associated with poor survival in gastric cancer patients. Neoplasma. 2013; 60(4):439-45. DOI: 10.4149/neo_2013_057. View

11.

Hara T, Abe M, Inoue H, Yu L, Veenstra T, Kang Y . Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase. Oncogene. 2005; 25(4):566-78. DOI: 10.1038/sj.onc.1209078. View

12.

Zhang H, Yin Z, Ning K, Wang L, Guo R, Ji Z . Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma. Hum Pathol. 2014; 45(7):1430-6. DOI: 10.1016/j.humpath.2014.02.018. View

13.

Hirata D, Yamabuki T, Miki D, Ito T, Tsuchiya E, Fujita M . Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res. 2009; 15(1):256-66. DOI: 10.1158/1078-0432.CCR-08-1672. View

14.

Saito S, Liu X, Kamijo K, Raziuddin R, Tatsumoto T, Okamoto I . Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. J Biol Chem. 2003; 279(8):7169-79. DOI: 10.1074/jbc.M306725200. View

15.

Sano M, Genkai N, Yajima N, Tsuchiya N, Homma J, Tanaka R . Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep. 2006; 16(5):1093-8. View

16.

Miki T, Smith C, Long J, Eva A, Fleming T . Oncogene ect2 is related to regulators of small GTP-binding proteins. Nature. 1993; 362(6419):462-5. DOI: 10.1038/362462a0. View

17.

Fields A, Justilien V . The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv Enzyme Regul. 2009; 50(1):190-200. PMC: 2863999. DOI: 10.1016/j.advenzreg.2009.10.010. View

18.

Zhang M, Lu S, Zhou L, Zheng S . Correlation between ECT2 gene expression and methylation change of ECT2 promoter region in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008; 7(5):533-8. View

19.

Wang W, Li J, Du L, Wang L, Yang Y, Liu Y . Krüppel-like factor 8 overexpression is correlated with angiogenesis and poor prognosis in gastric cancer. World J Gastroenterol. 2013; 19(27):4309-15. PMC: 3718898. DOI: 10.3748/wjg.v19.i27.4309. View

20.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View